IVEY WALKER: Open Payments
NPI 1215678487 · GRAPEVINE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,617 in 44 payments from 18 companies in 2025. Trend: 2023 $1,512 · 2024 $1,248 · 2025 $2,617
Food & beverage: $1,419Long term medical supply or device loan: $1,196Speaker / faculty: $2
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $1,230 |
| Daiichi Sankyo Inc. | 6 | $246 |
| Janssen Biotech, Inc. | 2 | $215 |
| Myriad Genetic Laboratories, Inc. | 3 | $215 |
| PFIZER INC. | 2 | $140 |
| AstraZeneca Pharmaceuticals LP | 1 | $114 |
| Stemline Therapeutics Inc. | 1 | $109 |
| Lilly USA, LLC | 2 | $56 |
| Karyopharm Therapeutics Inc. | 2 | $48 |
| Gilead Sciences, Inc. | 2 | $43 |
Products named: KISQALI, Enhertu, RYBREVANT, MYRISK, BRAFTOVI, ELZONRIS, VERZENIO, XPOVIO.
Industry payments across TX — which companies pay providers there.
